Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5844033 | Pharmacology & Therapeutics | 2013 | 8 Pages |
Abstract
The role of glucagon-like peptide 2 (GLP2) in colon tissue has been studied extensively, from the time it was discovered that GLP2 promotes intestinal growth. A large number of studies have shown potential applications for GLP2 in human therapy. However, recent data have suggested the notion that GLP2 plays a key role in colon carcinogenesis. Questions have been arisen regarding the pro-proliferative effects of GLP2 and whether they might promote intestinal healing or advance colon tumor growth. Here, we provide striking evidence to show that the physiological activities of GLP2 are closely related to cancer-related molecular pathways that have been shown to circumvent drug desensitization. We further explore the different pathways of GLP2-signaling to suggest suitable GLP2-based therapeutic strategies in colon cancer.
Keywords
TGF-βGLP1PI3KCDKCAFsGSK-3DPP-IVAPCIGF-1GSK-3βIGF-1Radenomatous polyposis coliAktTransforming growth factor βProliferationdipeptidyl peptidase IVCancer therapyColon cancerinsulin-like growth factor 1phosphatidylinositol 3 kinase5-fluorouracilCarcinoma-associated fibroblastsprotein kinase Bglucagon-like peptide 2cyclin-dependent kinaseglycogen synthase kinase 3glycogen synthase kinase 3 βinsulin-like growth factor 1 receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Vinicius Kannen, Sergio Britto Garcia, Helga Stopper, Ana Maria Waaga-Gasser,